INmune Bio Earnings Estimate

INMB Stock  USD 1.51  0.09  6.34%   
By analyzing INmune Bio's earnings estimates, investors can diagnose different trends across INmune Bio's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for INmune Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
INmune Bio is projected to generate -0.4025 in earnings per share on the 31st of December 2025. INmune Bio earnings estimates show analyst consensus about projected INmune Bio EPS (Earning Per Share). It derives the highest and the lowest estimates based on INmune Bio's historical volatility. Many public companies, such as INmune Bio, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing INmune Bio's earnings estimates, investors can diagnose different trends across INmune Bio's analyst sentiment over time as well as compare current estimates against different timeframes. As of February 8, 2026, Gross Profit is expected to decline to about 12 K. The current year's Pretax Profit Margin is expected to grow to -3,284Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

INmune Bio Earnings per Share Projection vs Actual

About INmune Bio Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of INmune Bio earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current INmune Bio estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as INmune Bio fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-146.8 M-139.5 M
Retained Earnings Total Equity-81.9 M-77.8 M
Earnings Yield(0.52)(0.49)
Price Earnings Ratio(1.99)(2.09)
Price Earnings To Growth Ratio(0.08)(0.08)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. Market participants price INmune higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive INmune Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(2.08)
Revenue Per Share
0.002
Quarterly Revenue Growth
2.571
Return On Assets
(0.51)
Return On Equity
(1.56)
INmune Bio's market price often diverges from its book value, the accounting figure shown on INmune's balance sheet. Smart investors calculate INmune Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since INmune Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.